Sound View Wealth Advisors LLC purchased a new stake in shares of Celgene Co. (NASDAQ:CELG) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,460 shares of the biopharmaceutical company’s stock, valued at approximately $350,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in CELG. BlackRock Inc. boosted its position in Celgene by 2.8% during the fourth quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after purchasing an additional 1,459,100 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of Celgene by 9,691.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 16,327,522 shares during the period. Edgewood Management LLC raised its position in Celgene by 13.2% during the third quarter. Edgewood Management LLC now owns 15,757,525 shares of the biopharmaceutical company’s stock valued at $1,410,141,000 after acquiring an additional 1,832,981 shares in the last quarter. Janus Henderson Group PLC raised its position in Celgene by 15.3% during the third quarter. Janus Henderson Group PLC now owns 10,461,658 shares of the biopharmaceutical company’s stock valued at $936,215,000 after acquiring an additional 1,391,617 shares in the last quarter. Finally, FMR LLC raised its position in Celgene by 26.0% during the third quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock valued at $919,890,000 after acquiring an additional 2,119,257 shares in the last quarter. 73.64% of the stock is currently owned by institutional investors and hedge funds.
CELG stock traded up $0.24 during mid-day trading on Tuesday, reaching $85.50. 63,866 shares of the stock traded hands, compared to its average volume of 12,552,355. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $95.30. The stock has a market capitalization of $59.46 billion, a price-to-earnings ratio of 11.21, a price-to-earnings-growth ratio of 0.40 and a beta of 1.72.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 125.35%. The company had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same period in the prior year, the company earned $2.00 earnings per share. Equities analysts expect that Celgene Co. will post 10.01 EPS for the current fiscal year.
In other news, Director Ernest Mario purchased 2,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was bought at an average cost of $89.99 per share, for a total transaction of $179,980.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the sale, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.
A number of analysts have recently issued reports on CELG shares. reaffirmed a “buy” rating on shares of Celgene in a research note on Monday, December 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 5th. Citigroup cut their price objective on Celgene from $100.00 to $77.00 and set a “neutral” rating on the stock in a report on Monday, December 17th. Morgan Stanley cut their price objective on Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 19th. Finally, BTIG Research initiated coverage on Celgene in a report on Thursday, December 20th. They issued a “neutral” rating on the stock. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $100.94.
TRADEMARK VIOLATION NOTICE: “Sound View Wealth Advisors LLC Takes $350,000 Position in Celgene Co. (CELG)” was posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.fairfieldcurrent.com/news/2019/03/12/sound-view-wealth-advisors-llc-takes-350000-position-in-celgene-co-celg.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What are the benefits of momentum investing?
Receive News & Ratings for Celgene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene and related companies with MarketBeat.com’s FREE daily email newsletter.